3-({5-[(3-Carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: 3-({5-[(3-Carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
• 英文别名: 3-[5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
• 化学式: C₂₂H₂₅N₃O₇S
• 分子量: 475.5
• InChiKey: JUZNIMUFDBIJCM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  182
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• US9308263B2
  申请人：——

  公开号：US9308263B2

  公开（公告）日：2016-04-12
• [EN] PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：SEACHAID PHARMACEUTICALS INC

  公开号：WO2013059664A1

  公开（公告）日：2013-04-25

  The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug.
• [EN] ARTICLES COMPRISING STEROID DIMERS AND THEIR USE IN THE DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] ARTICLES COMPRENANT DES DIMÈRES STÉROÏDES ET LEUR UTILISATION DANS L'ADMINISTRATION D'AGENTS THÉRAPEUTIQUES
  申请人：RIPPLE THERAPEUTICS CORP

  公开号：WO2021014217A1

  公开（公告）日：2021-01-28

  The present invention is directed towards articles comprising a steroid material comprising a steroid dimer and at least one therapeutic agent distributed throughout the steroid material and the use of such articles in sustained release delivery systems. Said article may be fibers, fiber meshes, woven fabrics, non-woven fabrics, films, pellets, cylinders, microparticles, nanoparticles, shaped articles or coatings on a substrate (such as an implant). Control of the release profile of the at least one therapeutic agent can be achieved via selection of the steroids within the steroid dimer, the linker conjugating the steroids within the dimer, the linkage groups between the steroids and the linker, the surface area of the article, the location of the at least one therapeutic agent within the article and the amount of the at least one therapeutic agent within the article.